FDA approves first treatment for paediatric patients with lupus

FDA

26 April 2019 - The U.S. FDA today approved Benlysta (belimumab) intravenous infusion for treatment of children with systemic lupus erythematosus – often referred to as simply “lupus” – a serious chronic disease that causes inflammation and damage to various body tissues and organs. 

This is the first time that the FDA has approved a treatment for paediatric patients with systemic lupus erythematosus (SLE). Benlysta has been approved for use in adult patients since 2011.

The efficacy of intravenous Benlysta for the treatment of SLE in paediatric patients was studied over 52 weeks in 93 paediatric patients with SLE.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics